Biotech Values

[DewDiligence]

>MNTA – The one that didn't work out was the other lmwh, I can't remember the name. It's not listed on the mnta pipeline chart so I assume its dead.<

The defunct program is dalteparin a.k.a. Fragmin, which MNTA canned because the branded drug has been a commercial flop.

Unlike Lovenox, which is approved for both acute and chronic indications, Fragmin is approved only for acute indications (with the exception of treating DVT secondary to cancer).